BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27528224)

  • 1. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
    Zoratti GL; Tanabe LM; Hyland TE; Duhaime MJ; Colombo É; Leduc R; Marsault E; Johnson MD; Lin CY; Boerner J; Lang JE; List K
    Oncotarget; 2016 Sep; 7(36):58162-58173. PubMed ID: 27528224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
    Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
    Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
    Zoratti GL; Tanabe LM; Varela FA; Murray AS; Bergum C; Colombo É; Lang JE; Molinolo AA; Leduc R; Marsault E; Boerner J; List K
    Nat Commun; 2015 Apr; 6():6776. PubMed ID: 25873032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
    Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
    Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
    Fang JD; Lee SL
    Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
    Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatocyte growth factor regulatory factors in human breast cancer.
    Parr C; Watkins G; Mansel RE; Jiang WG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
    Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
    Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
    Yamasaki K; Mukai S; Nagai T; Nakahara K; Fujii M; Terada N; Ohno A; Sato Y; Toda Y; Kataoka H; Kamoto T
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
    Szabo R; Rasmussen AL; Moyer AB; Kosa P; Schafer JM; Molinolo AA; Gutkind JS; Bugge TH
    Oncogene; 2011 Apr; 30(17):2003-16. PubMed ID: 21217780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
    Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
    Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
    Damalanka VC; Janetka JW
    Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
    Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
    Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
    Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
    Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.
    Victor BC; Anbalagan A; Mohamed MM; Sloane BF; Cavallo-Medved D
    Breast Cancer Res; 2011; 13(6):R115. PubMed ID: 22093547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
    Ye F; Chen S; Liu X; Ye X; Wang K; Zeng Z; Su Y; Zhang XK; Zhou H
    J Cell Mol Med; 2019 Jan; 23(1):155-166. PubMed ID: 30370662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
    Parr C; Jiang WG
    Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation.
    Lee SL; Huang PY; Roller P; Cho EG; Park D; Dickson RB
    Mech Dev; 2010; 127(1-2):82-95. PubMed ID: 19853659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
    Uhland K; Siphos B; Arkona C; Schuster M; Petri B; Steinmetzer P; Mueller F; Schweinitz A; Steinmetzer T; Van De Locht A
    Int J Oncol; 2009 Aug; 35(2):347-57. PubMed ID: 19578749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.